Trial Profile
ADRENL - ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children, Pilot Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Corticotropin (Primary)
- Indications Lipoid nephrosis; Nephrotic syndrome
- Focus Therapeutic Use
- Acronyms ADRENL
- 19 Apr 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Jan 2018 Location has been assumed according to the information provided in the source.
- 29 Jan 2018 New trial record